Target
Ki67
3 abstracts
Abstract
Evaluating Ki67 and Oncotype DX Breast Recurrence Score during neoadjuvant treatment with letrozole/abemaciclib or chemotherapy in patients with highly proliferative HR+/HER2- breast cancer participating in the GEICAM CARABELA trial.Org: Spanish Breast Cancer Group, Málaga,
Abstract
Clinical significance of circulating tumor DNA in neoadjuvant-treated HER2-negative luminal B breast cancer.Org: Genecast Biotechnology Co., Ltd, Beijing, China,
Abstract
Identifying anatomopathological factors associated with a Oncotype DX 21-gene recurrence score higher than 25 in menopaused women.Org: Assistance Publique des Hôpitaux de Paris, Hôpital Tenon, Institut Universitaire de Cancérologie, Sorbonne Université, APHP-INSERM U1149 Universite Paris Diderot,